Pimavanserin

Phase 2/3Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Irritability Associated With Autism Spectrum Disorder

Conditions

Irritability Associated With Autism Spectrum Disorder

Trial Timeline

Nov 2, 2022 → Feb 14, 2025

NCT ID

NCT05555615

About Pimavanserin

Pimavanserin is a phase 2/3 stage product being developed by Acadia Pharmaceuticals for Irritability Associated With Autism Spectrum Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT05555615. Target conditions include Irritability Associated With Autism Spectrum Disorder.

What happened to similar drugs?

1 of 5 similar drugs in Irritability Associated With Autism Spectrum Disorder were approved

Approved (1) Terminated (0) Active (4)

🔄KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3

✅Aripiprazole + PlaceboBristol Myers SquibbApproved

🔄Brexpiprazole + PlaceboLundbeckPhase 3

🔄BrexpiprazoleLundbeckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05796167	Phase 1	Withdrawn	Jan 27, 2023	Jun 24, 2024	Parkinson Disease
NCT05357612	Approved	Recruiting	Jan 23, 2023	Aug 1, 2026	Neurodegenerative Diseases
NCT04809116	Approved	Withdrawn	Dec 15, 2022	Dec 15, 2023	Insomnia Chronic
NCT05555615	Phase 2/3	Terminated	Nov 2, 2022	Feb 14, 2025	Irritability Associated With Autism Spectrum Disorder
NCT04292223	Approved	Completed	Feb 10, 2020	Apr 26, 2022	Parkinson Disease Psychosis
NCT04000009	Phase 3	Terminated	Jun 6, 2019	Feb 22, 2021	Adjunctive Treatment of Major Depressive Disorder
NCT03623321	Phase 3	Completed	Jul 17, 2018	May 5, 2023	Neuropsychiatric Symptoms Related to Neurodegenerative Disease
NCT03482882	Phase 2	Completed	Mar 9, 2018	Jul 24, 2019	Treatment of Depression in Adults With Parkinson's Disease (PD)
NCT03118947	Phase 2	Completed	Feb 23, 2017	Feb 25, 2019	Agitation and Aggression in Alzheimer's Disease
NCT03121586	Phase 3	Terminated	Jan 1, 2017	May 30, 2024	Schizophrenia
NCT03018340	Phase 2	Completed	Dec 1, 2016	Oct 1, 2018	Adjunctive Treatment of Major Depressive Disorder

Competing Products

7 competing products in Irritability Associated With Autism Spectrum Disorder

See all competitors

Product	Company	Stage	Hype Score
KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo	Bristol Myers Squibb	Phase 3	47
KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo	Bristol Myers Squibb	Phase 3	47
Aripiprazole + Placebo	Bristol Myers Squibb	Approved	43
Brexpiprazole + Placebo	Lundbeck	Phase 3	37
Brexpiprazole	Lundbeck	Phase 3	37
JZP541	Jazz Pharmaceuticals	Phase 2	24
Pimavanserin + Placebo	Acadia Pharmaceuticals	Phase 2/3	35